ThromboGenics: Clinical Trials

31 trials sponsored by ThromboGenics, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

25 completed, 5 terminated, 1 unknown. 19 Phase 2, 5 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 219Completed 13, Terminated 5, Unknown 1
Phase 15Completed 5
Phase 33Completed 3

Follow ThromboGenics: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)
Eplerenone - Vitreomacular Traction, Subretinal Edema
Phase 2TerminatedWagner Macula & Retina Center22019-10-042021-01-08
A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)
THR-317 8mg - Retinal Telangiectasis, Idiopathic Juxtafoveal Retinal Telangiectasia
Phase 2CompletedThromboGenics82018-09-182020-09-02
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
THR-687 dose level 1, THR-687 dose level 2, THR-687 dose level 3 - Diabetes Mellitus, Diabetic Retinopathy
Phase 1CompletedThromboGenics122018-09-172020-01-22
A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)
THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3 - Diabetes Mellitus, Diabetic Retinopathy
Phase 1CompletedThromboGenics122018-05-182019-06-13
A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)
Anti-PlGF recombinant monoclonal antibody, 4mg dose, Anti-PlGF recombinant monoclonal antibody, 8mg dose - Diabetic Retinopathy, Macular Edema
Phase 2CompletedThromboGenics492016-12-222018-04-17
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
ocriplasmin 0.0625mg, ocriplasmin 0.125mg, Sham injection - Diabetic Retinopathy, Posterior Vitreous Detachment
Phase 2TerminatedThromboGenics482015-12-012020-12-16
A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA
Symptomatic Vitreomacular Adhesion (VMA)
CompletedThromboGenics1342014-08-012015-07-09
Prevalence of Vitreomacular Adhesion in Patients 40 Years and Older
Vitreomacular Adhesion
CompletedNova Southeastern University15842014-05-012018-03-29
Ocriplasmin Research to Better Inform Treatment (ORBIT)
Symptomatic Vitreomacular Adhesion
CompletedThromboGenics5402014-05-012016-06-21
Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
Ocriplasmin, Sham injection - Vitreomacular Adhesion Including Macular Hole
Phase 3CompletedThromboGenics2202011-10-012016-03-14
Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies
ocriplasmin, placebo - Symptomatic Vitreomacular Adhesion
CompletedThromboGenics242011-05-012017-01-13
Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
TB-402, Rivaroxaban - Prophylaxis of Venous Thromboembolic Events
Phase 2CompletedThromboGenics6322011-04-012012-08-23
The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
ocriplasmin - Vitrectomy
Phase 2CompletedThromboGenics382010-07-012014-12-17
Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
Ocriplasmin, Placebo - Vitrectomy
Phase 2CompletedThromboGenics242010-02-012014-12-17
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
Ocriplasmin, Sham injection - Exudative Age-Related Macular Degeneration, Focal Vitreomacular Adhesion
Phase 2CompletedThromboGenics1002010-01-012014-12-17
Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion
Microplasmin - Focal Vitreomacular Adhesion
Phase 2CompletedThromboGenics172010-01-012014-04-07
Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
Microplasmin, Placebo control - Macular Degeneration
Phase 2UnknownUniversity of California, Los Angeles302009-10-012011-09-27
Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery
TB-402, Enoxaparin - Total Knee Replacement Surgery
Phase 2CompletedThromboGenics3162008-12-012014-04-07
Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
Ocriplasmin 125µg, Placebo - Vitreomacular Adhesion
Phase 3CompletedThromboGenics3262008-12-012014-12-17
Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
125 µg Ocriplasmin, Placebo - Vitreomacular Adhesion
Phase 3CompletedThromboGenics3262008-12-012014-12-17

Showing 20 of 31. Sign in to see all of them.

Conditions studied

Diabetic Retinopathy (5)  ·  Diabetes Mellitus (2)  ·  Macular Degeneration (2)  ·  Stroke (2)  ·  Vitreous Detachment (2)  ·  Arterial Occlusive Diseases (1)  ·  Disease Progression (1)  ·  Eye Diseases (1)  ·  Idiopathic Juxtafoveal Retinal Telangiectasia (1)  ·  Ischemic Stroke (1)  ·  Macular Edema (1)  ·  Retinal Perforations (1)  ·  Retinal Telangiectasis (1)  ·  Thromboembolism (1)  ·  Venous Thrombosis (1)

Interventions

microplasmin (18)  ·  TB 402 (5)  ·  salicylhydroxamic acid (4)  ·  Enoxaparin (1)  ·  Eplerenone (1)  ·  Rivaroxaban (1)  ·  TB-403 (1)

Countries

United States (15)  ·  Belgium (11)  ·  Germany (7)  ·  Netherlands (4)  ·  United Kingdom (4)  ·  Czechia (3)  ·  Denmark (3)  ·  France (3)  ·  Hungary (3)  ·  Italy (3)  ·  Poland (3)  ·  Spain (3)  ·  Austria (2)  ·  Bulgaria (2)  ·  Israel (2)

Top investigators

Thomas J Jensen, MD, PhD (2)  ·  Gerard O'Sullivan, MD (1)  ·  Gerhard Hamann, Prof. Dr (1)  ·  Julie A Rodman, OD, MS, FAAO (1)  ·  Peter Verhamme, MD, PhD (1)  ·  Steven D Schwartz, M.D. (1)  ·  Thomas J Jensen, M.D. (1)  ·  Vincent Thijs, MD PhD (1)

Results publications

PMID 22879421, PMID 22894573, PMID 23033391, PMID 26068086, PMID 20637972, PMID 23982845, PMID 30350717, PMID 30935657, PMID 34250257

NIH funding

2015 (1), 2016 (1), 2017 (1)